InvestorsHub Logo
Followers 6
Posts 461
Boards Moderated 0
Alias Born 11/13/2013

Re: DonShimoda post# 54821

Thursday, 10/09/2014 12:01:33 PM

Thursday, October 09, 2014 12:01:33 PM

Post# of 80490

...I'm shocked to see the level of support Berger continues to receive from some here. The only explanation that makes sense to me is that they must be suffering from Stockholm syndrome. Let's not forget that at the same time Harvey Berger was telling investors the Iclusig AE's were no big deal, the FDA had already approached the company about the issue...


Let’s put yourself in Harvey Berger’s shoe, as an inventor of the product, after years of trials and you had confidence for it going to the market, wouldn’t you do the exact same thing which is to defend vigorously when someone questioning your product? Harvey Berger do nothing wrong, that’s why so far no one could sue him for those statements he made.

The one should be blamed and should be sued for your huge investment loss due the crash last October is FDA, not Ariad. There is something fundamentally wrong in the way the agency handling drugs safety assessment. We human in general are physically different; some are highly fit and strong which can easily handle high dosage; while those weak/skinny/or obesity and their body typically experiencing some other medical issues, a smaller dosage could still be too strong to them. Therefore, it’s just doesn’t make sense at all for looking into a common dosage applied for all especially when dealing with those highly potent cancer drugs. Each cancer patient should be carefully studied by doctor and come up with proper dosage specifically customized for the patient based on their health/physical condition. And because of this, the doctor’s skills in administering the patients absolutely have a huge impact on the end results. Therefore, the agency should have spent more time studying the reports before coming up the decision. The truth is that Iclusig is a life-saving drug and patient/doctors desperately needed the drug, that’s why FDA had to quickly reverse their decision within a very short period of time, but for saving their face they came a label-restriction on the drug.

ARIA stock price being traded at this level has nothing to do with Harvey Berger as the CEO. It is the >30% short-interest is holding the stock price hostage at this level. A little analysis on the monthly short interest changes between 10/13 -> 01/14, one would see ~15 million shares shorted in the $2 -> $3 price level. Being caught by surprise by FDA’s quickly decision for having Iclusig back to the market, those shorts should have quickly covered their positions, unfortunately their greediness made them holding on the shares, and started spreading all kind of negative stuffs against Ariad via the unreliable news sources like SeekingAlpha, The Street.com and message boards like iHub. According to the messages posted on ihub, it seems one of their strategies is to cause chaos/disruption within the company, and there is nothing better for this to happen is to start a war between Denner vs. Harvey Berger. They interpreted Denner’s decision of wanting to buy more shares as he’s seeking to gain more control power of the company, so that he could oust HB. They knew damn well that Denner would never be successfully in doing so for Harvey, as the company founder with a very deep root in the company, and having the majority of the board members recruited by him. But Denner failed in ousting HB, would only cause everything messy and would lead to ARIA share price to fall further so that they could benefit out of it. What if, Denner’s decision is simply because he wanted more shares of Ariad for he’s seeing lot of potential in the company while ARIA being traded at this level?
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.